These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 3457877)
1. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers]. Kawai M; Yamashita H; Hayashi T; Kamiya N; Kakihara M; Arii Y Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877 [TBL] [Abstract][Full Text] [Related]
2. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms]. Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349 [TBL] [Abstract][Full Text] [Related]
3. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers]. Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666 [TBL] [Abstract][Full Text] [Related]
4. [Significance of tumor markers in the treatment of patients with ovarian malignancies]. Tomoda Y; Kano T; Furuhashi Y; Mizuno K; Kamiya N; Mizuno K; Sakakibara K; Ohta M Gan To Kagaku Ryoho; 1987 Nov; 14(11):3027-33. PubMed ID: 2445293 [TBL] [Abstract][Full Text] [Related]
5. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392 [TBL] [Abstract][Full Text] [Related]
6. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin. Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639 [TBL] [Abstract][Full Text] [Related]
7. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors]. Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801 [TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer]. Kimura E; Murae M; Koga R; Odawara Y; Nakabayashi Y; Yokoyama K; Nakata H; Totake T; Ochiai K; Yasuda M Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320 [TBL] [Abstract][Full Text] [Related]
9. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors]. Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374 [TBL] [Abstract][Full Text] [Related]
10. [Serum CA125 and CA19-9 levels in adenocarcinoma of the uterine cervix and endometrial carcinoma]. Ihara Y; Shimizu T; Kawaguchi K; Yomura W; Fujiwara T; Inoue K Nihon Sanka Fujinka Gakkai Zasshi; 1988 Nov; 40(11):1711-8. PubMed ID: 3235884 [TBL] [Abstract][Full Text] [Related]
11. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers]. Kataoka A; Yakushiji M Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782 [TBL] [Abstract][Full Text] [Related]
12. [The preparation and clinical use of a radioimmunoassay CA125 kit for the diagnosis of epithelial ovarian cancer]. Liu W Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Dec; 14(6):469-72. PubMed ID: 1303823 [TBL] [Abstract][Full Text] [Related]
13. [Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity]. Oishi T; Maruo T; Iwasaki M; Mochizuki M Nihon Sanka Fujinka Gakkai Zasshi; 1986 Sep; 38(9):1595-604. PubMed ID: 3464659 [TBL] [Abstract][Full Text] [Related]
14. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer]. Kobayashi H Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289 [TBL] [Abstract][Full Text] [Related]
15. Roles of CA125 in patients with ovarian cancer--usefulness in periodical monitoring. Kawai M; Inagaki S; Yamashita H; Imaizumi H; Kakihara M; Arii Y Nihon Gan Chiryo Gakkai Shi; 1988 May; 23(5):1059-67. PubMed ID: 3166484 [No Abstract] [Full Text] [Related]
16. Evaluation of CA125 as a circulating tumor marker for ovarian cancer. Kuzuya K; Nozaki M; Chihara T Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):949-57. PubMed ID: 3461071 [TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of specificity of serum CA125 as a tumor marker of ovarian carcinoma]. Iwasaka T; Ohkuma Y; Yoshimura T; Sugimori H Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):917-23. PubMed ID: 2426378 [TBL] [Abstract][Full Text] [Related]
19. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer. Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265 [TBL] [Abstract][Full Text] [Related]
20. Serum and tissue measurements of CA72-4 in ovarian cancer patients. Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]